Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears AdvanDx Fungal Test Speed-up

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics test developer AdvanDx said today that it has received 510(k) clearance from the US Food and Drug Administration for a new protocol that speeds up results for two of its tests for fungal bloodstream infection.

The protocol cleared by FDA reduces the time for results for its PNA FISH tests for Candida albicans and for C. glabrata from two 2.5 hours to 90 minutes.

Reducing the time to identify these two hospital-acquired Candida infections, which affect more than 24,000 patients in the US each year, enables physicians to begin treating patients more swiftly with the correct course of antifungal therapy. Because a new class of antifungal drugs work broadly against Candida species but are substantially more expensive than a generic antifungal agent, a test to identify which course to take can save money and enhance treatment, the firm said.

Candidemia, the bloodstream infection caused by Candida species, can have mortality rates as high as 50 percent among patients with compromised immune systems after transplants, and those with AIDS and cancer, according to AdvanDx.

The PNA FISH test is a fluorescence in situ hybridization assay that uses peptide nucleic acid probes to target species-specific ribosomal RNA that live in bacteria and yeast.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.